Multiple Sclerosis – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Multiple Sclerosis – Pipeline Review, H1 2020’, provides an overview of the Multiple Sclerosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Multiple Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Multiple Sclerosis

– The report reviews pipeline therapeutics for Multiple Sclerosis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Multiple Sclerosis therapeutics and enlists all their major and minor projects

– The report assesses Multiple Sclerosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Multiple Sclerosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Multiple Sclerosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4D Pharma Plc

AB Science SA

AbbVie Inc

Abeome Corp

Abion Inc

Abivax SA

Abreos Biosciences Inc

Accure Therapeutics SL

Acelerox LLC

Actelion Pharmaceuticals Ltd

Aequus Pharmaceuticals Inc

Affectis Pharmaceuticals AG

AgoneX Biopharmaceuticals Inc

Ahead Therapeutics SL

Akaal Pharma Pty Ltd

Alexion Pharmaceuticals Inc

Alpha Cancer Technologies Inc

Alpine Immune Sciences Inc

Altheia Science SRL

Amgen Inc

Anavex Life Sciences Corp

Ankar Pharma SL

Anokion SA

Antisense Therapeutics Ltd

AnTolRx Inc

Anvyl LLC

Apaxen

Aphios Corp

Apimeds Inc

Apitope International NV

Aprilbio Co Ltd

Artax Biopharma Inc

Asdera LLC

AstraZeneca Plc

Atara Biotherapeutics Inc

Athersys Inc

Athira Pharma Inc

Atlantic Bio Sci LLC

Autobahn Therapeutics Inc

Autoimmunity Biologic Solutions Inc

Avicanna Inc

Axial Biotherapeutics Inc

Axxam SpA

Barricade Therapeutics Corp

Bayer AG

Baylx Inc

BioAegis Therapeutics Inc

BioApex sro

Biocad

Biocon Ltd

Biocure Technology Inc

Biogen Inc

BioIncept LLC

Biond Biologics Ltd

Biovista Inc

Bolder Biotechnology Inc

Boston Pharmaceuticals Inc

BrainStorm Cell Therapeutics Inc

Bridge Biotherapeutics Inc

Bristol-Myers Squibb Co

BTB Pharma AB

Califia Bio Inc

Cardinal Therapeutics Inc

CavoGene LifeSciences

Cerion LLC

CGeneTech (Suzhou China) Co Ltd

Chipscreen Biosciences Ltd

Cinnagen Co

Clene Nanomedicine Inc

Coherus BioSciences Inc

Commence Bio Inc

Complement Pharma BV

Compugen Ltd

Convelo Therapeutics Inc

Corium, Inc.

Cour Pharmaceuticals Development Co Inc

Curadim Pharma Co Ltd

CuraVac Inc

CuroNZ Ltd

Curyx Bio Inc

Cyteir Therapeutics Inc

Cytocom Inc

Cytodyn Inc

Cyxone AB

DC4U BV

Denali Therapeutics Inc

DiNonA Inc

Disarm Therapeutics Inc

Dr. Reddy's Laboratories Ltd

Druggability Technologies Holdings Ltd

Dualogics Corp

EA Pharma Co Ltd

Eldrug SA

Eli Lilly and Co

Emerald Health Sciences Inc

Endece LLC

EnhanX Biopharm Inc

Enterin Inc

Epitracker Inc

Eton Pharmaceuticals Inc

Evgen Pharma Plc

F. Hoffmann-La Roche Ltd

Farmacija d.o.o. Tuzla

FibroGenesis LLC

Fortuna Fix Inc

Frequency Therapeutics Inc

GABA Therapeutics Inc

Gemac SA

Genervon Biopharmaceuticals LLC

GeNeuro SA

Gilead Sciences Inc

GlaxoSmithKline Plc

Glialogix Inc

Glixis Therapeutics LLC

Glixogen Therapeutics

Handa Pharmaceuticals LLC

Humabs BioMed SA

HuniLife Biotechnology Inc

Hutchison MediPharma Ltd

IL-2Rx Inc

Iltoo Pharma

ImCyse SA

Immune Response BioPharma Inc

Immungenetics AG

Immunic Inc

Immunwork Inc

ImmusanT Inc

Immutep Ltd

Impetis Biosciences Ltd

Imstem Biotechnology Inc

Inflazome Ltd

Inmune Bio Inc

InnoBioscience LLC

Innovimmune Biotherapeutics Inc

InSight Biopharmaceuticals Ltd

Io Therapeutics Inc

Istesso Ltd

J2H Biotech

Jura Bio Inc

Jyant Technologies Inc

Karo Pharma AB

Klogene Therapeutics Inc

Kogenix Therapeutics Inc

Kyorin Pharmaceutical Co Ltd

Landos Biopharma Inc

Lead Discovery Center GmbH

Leukosight Inc

LFB SA

LIFNano Rx Ltd

Llama Therapeutics Inc

Mabion SA

MAKScientific LLC

Mapi Pharma Ltd

Maruho Co Ltd

Med-Life Discoveries LP

MedAnnex Ltd

MedDay SA

Medicenna Therapeutics Corp

Merck KGaA

Meta-IQ ApS

MetiMedi Pharmaceuticals Co Ltd

MetrioPharm AG

Millennium Pharmaceuticals Inc

Mirae Cell Bio Co Ltd

Mitochon Pharmaceuticals Inc

Mitotech SA

Mitsubishi Tanabe Pharma Corp

MMJ International Holdings Corp

Mochida Pharmaceutical Co Ltd

Molecules For Health Inc

MorphoSys AG

Mount Tam Biotechnologies Inc

MyMD Pharmaceuticals Inc

NervGen Pharma Corp

Neuren Pharmaceuticals Ltd

Neuro Vigor LLC

Neurodegeneration Therapeutics Inc

Neurotrope Bioscience Inc

New World Laboratories Inc

Novartis AG

Novoron Bioscience Inc

Numab Therapeutics AG

Omeros Corp

Oncodesign SA

OncoImmune Inc

Op-T-Mune Inc

Orion Biotechnology Canada Ltd

Orpheris Inc

Oryzon Genomics SA

Oscine Therapeutics

OSE Immunotherapeutics

Ossianix Inc

Pahan Therapeutics

Pangen Biotech Inc

Par'Immune SAS

Parkside Scientific Inc

PharmatrophiX Inc

PharmCADD Co Ltd

Pheno Therapeutics Ltd

Pipeline Therapeutics Inc

Polpharma Biologics

PolTREG Sp z o o

Principia Biopharma Inc

Progenitor Therapeutics Ltd

Promethera Biosciences SA

ProNoxis AB

Proteorex Therapeutics Inc

Provid Pharmaceuticals Inc

Q Therapeutics Inc

Quimatryx SL

Reata Pharmaceuticals Inc

ReceptoPharm Inc

RedHill Biopharma Ltd

RegeneRx Biopharmaceuticals Inc

RemeGen Ltd

ReNeuroGen LLC

Renovo Neural Inc

Resverlogix Corp

Revalesio Corp

Reven Pharmaceuticals Inc

ReveraGen BioPharma Inc

Rewind Therapeutics NV

Rhizen Pharmaceuticals SA

Rigel Pharmaceuticals Inc

Riptide Bioscience Inc

Rodos BioTarget GmbH

Rubius Therapeutics Inc

SanBio Company Limited

Sangamo Therapeutics Inc

Sanofi

Sansho Co Ltd

Sarepta Therapeutics Inc

Sareum Holdings Plc

Scientus Pharma Inc

Seneca Biopharma Inc

Senju Pharmaceutical Co Ltd

Senzer Ltd

SK Chemicals Co Ltd

Stem Cell Medicine Ltd

Sujana Biotech, LLC

Suzhou Connect Biopharmaceuticals Ltd

Symbiotix Biotherapies Inc

SynAct Pharma AB

Takeda Pharmaceutical Co Ltd

Teikoku Pharma USA Inc

Tellus Therapeutics Inc

TeraImmune Inc

Tetra Therapeutics

Theratome Bio Inc

Therini Bio Inc

Tiziana Life Sciences Plc

Toleranzia AB

TolerogenixX GmbH

Tonix Pharmaceuticals Holding Corp

Topas Therapeutics GmbH

Transparency Life Sciences LLC

Trio Medicines Ltd

TwotoBiotech Ltd

UBI Pharma Inc

V Clinbio LLC

Vaccinex Inc

Vascular Biogenics Ltd

Vertex Pharmaceuticals Inc

Virogenomics BioDevelopment Inc

Virtici LLC

Vitalis LLC

Vitality Biopharma Inc

Xalud Therapeutics Inc

Xonovo Inc

ZyVersa Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Multiple Sclerosis - Overview

Multiple Sclerosis - Therapeutics Development

Multiple Sclerosis - Therapeutics Assessment

Multiple Sclerosis - Companies Involved in Therapeutics Development

Multiple Sclerosis - Drug Profiles

Multiple Sclerosis - Dormant Projects

Multiple Sclerosis - Discontinued Products

Multiple Sclerosis - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Multiple Sclerosis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Multiple Sclerosis – Pipeline by 4D Pharma Plc, H1 2020

Multiple Sclerosis – Pipeline by AB Science SA, H1 2020

Multiple Sclerosis – Pipeline by AbbVie Inc, H1 2020

Multiple Sclerosis – Pipeline by Abeome Corp, H1 2020

Multiple Sclerosis – Pipeline by Abion Inc, H1 2020

Multiple Sclerosis – Pipeline by Abivax SA, H1 2020

Multiple Sclerosis – Pipeline by Abreos Biosciences Inc, H1 2020

Multiple Sclerosis – Pipeline by Accure Therapeutics SL, H1 2020

Multiple Sclerosis – Pipeline by Acelerox LLC, H1 2020

Multiple Sclerosis – Pipeline by Actelion Pharmaceuticals Ltd, H1 2020

Multiple Sclerosis – Pipeline by Aequus Pharmaceuticals Inc, H1 2020

Multiple Sclerosis – Pipeline by Affectis Pharmaceuticals AG, H1 2020

Multiple Sclerosis – Pipeline by AgoneX Biopharmaceuticals Inc, H1 2020

Multiple Sclerosis – Pipeline by Ahead Therapeutics SL, H1 2020

Multiple Sclerosis – Pipeline by Akaal Pharma Pty Ltd, H1 2020

Multiple Sclerosis – Pipeline by Alexion Pharmaceuticals Inc, H1 2020

Multiple Sclerosis – Pipeline by Alpha Cancer Technologies Inc, H1 2020

Multiple Sclerosis – Pipeline by Alpine Immune Sciences Inc, H1 2020

Multiple Sclerosis – Pipeline by Altheia Science SRL, H1 2020

Multiple Sclerosis – Pipeline by Amgen Inc, H1 2020

Multiple Sclerosis – Pipeline by Anavex Life Sciences Corp, H1 2020

Multiple Sclerosis – Pipeline by Ankar Pharma SL, H1 2020Multiple Sclerosis – Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020

Multiple Sclerosis – Pipeline by Teikoku Pharma USA Inc, H1 2020

Multiple Sclerosis – Pipeline by Tellus Therapeutics Inc, H1 2020

Multiple Sclerosis – Pipeline by TeraImmune Inc, H1 2020

Multiple Sclerosis – Pipeline by Tetra Therapeutics, H1 2020

Multiple Sclerosis – Pipeline by Theratome Bio Inc, H1 2020

Multiple Sclerosis – Pipeline by Therini Bio Inc, H1 2020

Multiple Sclerosis – Pipeline by Tiziana Life Sciences Plc, H1 2020

Multiple Sclerosis – Pipeline by Toleranzia AB, H1 2020

Multiple Sclerosis – Pipeline by TolerogenixX GmbH, H1 2020

Multiple Sclerosis – Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2020

Multiple Sclerosis – Pipeline by Topas Therapeutics GmbH, H1 2020

Multiple Sclerosis – Pipeline by Transparency Life Sciences LLC, H1 2020

Multiple Sclerosis – Pipeline by Trio Medicines Ltd, H1 2020

Multiple Sclerosis – Pipeline by TwotoBiotech Ltd, H1 2020

Multiple Sclerosis – Pipeline by UBI Pharma Inc, H1 2020

Multiple Sclerosis – Pipeline by V Clinbio LLC, H1 2020

Multiple Sclerosis – Pipeline by Vaccinex Inc, H1 2020

Multiple Sclerosis – Pipeline by Vascular Biogenics Ltd, H1 2020

Multiple Sclerosis – Pipeline by Vertex Pharmaceuticals Inc, H1 2020

Multiple Sclerosis – Pipeline by Virogenomics BioDevelopment Inc, H1 2020

Multiple Sclerosis – Pipeline by Virtici LLC, H1 2020

Multiple Sclerosis – Pipeline by Vitalis LLC, H1 2020

Multiple Sclerosis – Pipeline by Vitality Biopharma Inc, H1 2020

Multiple Sclerosis – Pipeline by Xalud Therapeutics Inc, H1 2020

Multiple Sclerosis – Pipeline by Xonovo Inc, H1 2020

Multiple Sclerosis – Pipeline by ZyVersa Therapeutics Inc, H1 2020

Multiple Sclerosis – Dormant Projects, H1 2020

Multiple Sclerosis – Dormant Projects, H1 2020 (Contd..1), H1 2020

Multiple Sclerosis – Dormant Projects, H1 2020 (Contd..2), H1 2020

Multiple Sclerosis – Dormant Projects, H1 2020 (Contd..3), H1 2020

Multiple Sclerosis – Dormant Projects, H1 2020 (Contd..4), H1 2020

Multiple Sclerosis – Dormant Projects, H1 2020 (Contd..5), H1 2020

Multiple Sclerosis – Dormant Projects, H1 2020 (Contd..6), H1 2020

Multiple Sclerosis – Dormant Projects, H1 2020 (Contd..7), H1 2020

Multiple Sclerosis – Dormant Projects, H1 2020 (Contd..8), H1 2020

Multiple Sclerosis – Dormant Projects, H1 2020 (Contd..9), H1 2020

Multiple Sclerosis – Dormant Projects, H1 2020 (Contd..10), H1 2020

Multiple Sclerosis – Dormant Projects, H1 2020 (Contd..11), H1 2020

Multiple Sclerosis – Dormant Projects, H1 2020 (Contd..12), H1 2020

Multiple Sclerosis – Dormant Projects, H1 2020 (Contd..13), H1 2020

Multiple Sclerosis – Dormant Projects, H1 2020 (Contd..14), H1 2020

Multiple Sclerosis – Dormant Projects, H1 2020 (Contd..15), H1 2020

Multiple Sclerosis – Dormant Projects, H1 2020 (Contd..16), H1 2020

Multiple Sclerosis – Dormant Projects, H1 2020 (Contd..17), H1 2020

Multiple Sclerosis – Dormant Projects, H1 2020 (Contd..18), H1 2020

Multiple Sclerosis – Dormant Projects, H1 2020 (Contd..19), H1 2020

Multiple Sclerosis – Dormant Projects, H1 2020 (Contd..20), H1 2020

Multiple Sclerosis – Dormant Projects, H1 2020 (Contd..21), H1 2020

Multiple Sclerosis – Dormant Projects, H1 2020 (Contd..22), H1 2020

Multiple Sclerosis – Discontinued Products, H1 2020

Multiple Sclerosis – Discontinued Products, H1 2020 (Contd..1), H1 2020

Multiple Sclerosis – Discontinued Products, H1 2020 (Contd..2), H1 2020

List of Figures

List of Figures

Number of Products under Development for Multiple Sclerosis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports